Navigation Links
Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
Date:12/4/2007

ategic alternatives process. Nabi is now focused on building and realizing the significant value of Nabi's remaining assets including NicVax, our proprietary smoking cessation vaccine for treatment of nicotine addiction and prevention of smoking relapse, StaphVax, and our cash and PhosLo milestone and royalty opportunities," said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of gram positive bacterial infections and nicotine addiction. Nabi Biopharmaceuticals is currently developing NicVAX, an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and StaphVAX, a vaccine designed to prevent the most dangerous and prevalent strains of S. aureus bacterial infections. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.

Forward-Looking Statements

Statements in this release that are not strictly historical are forward- looking statements including statements about our strategic alternatives process and clinical trials and studies. You can identify these forward- looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our strategic alternatives process and our ability to: successfully partner with th
'/>"/>

SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
3. Eligard(R) six-month formulation successfully completes European approval procedure
4. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
7. GSI Securitization Completes Merger and Domicile Transfer
8. Medical Services International Inc. Completes Testing for European Union (EU) Application
9. Inverness Completes Acquisition of Cholestech
10. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
11. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... in Vietnam, The Nha Trang Institute of Vaccines and ... produced 5,000 doses of a H5N1 vaccine for// humans ... tested on white mice, guinea-pigs and cockerels and similar ... National Institute of Verification of Vaccines and Biological Products. ...
... human brain unique? Of the many explanations that can be ... myelin.// ,Conventional wisdom holds that myelin, the sheet ... fiber that conducts the neuron’s electrical impulses — is akin ... efficient signaling. But the research of UCLA neurology professor George ...
... delivered a male child on Wednesday at Holtz Children's Hospital. ... Ectopia// cordis. Seven or eight babies in a million are ... Naseem, was born with his heart outside his chest. The ... heart called pericardium had not developed in him. ...
... number of pounds women put on as they age, according ... by an Indian-American doctor.//,In a study that followed more than ... Dr Sanjay Patel of Case Western Reserve University in Cleveland ... put on less weight during middle age. ,The findings ...
... book is here that would thrill every gourmet. It is ... the year. It is a full course meal, daubed in ... goals. ,Brian Wansink is the brain behind this unique ... University Food and Brand Laboratory. Truly a gourmet, who enjoys ...
... a study shed light on a nagging mystery in neurobiology: ... pools of free zinc ions. Zinc - a new key ... signaling in the brain and spinal cord – says the ... affecting a neuronal zinc target, researchers have demonstrated a central ...
Cached Medicine News:Health News:Blame Myelin for Many Neuropsychiatric Disorders 2Health News:Naseem’s Heart Put In Its Plac 2Health News:Whet your appetite with “Mindless Eating”: A gourmet's deligh 2Health News:Whet your appetite with “Mindless Eating”: A gourmet's deligh 3Health News:Zinc – A New Key Player In Brain Circuitr 2
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
(Date:10/20/2014)... Oct. 20, 2014  Indianapolis interventional medical device ... Toronto -based 3D visualization leader Synaptive ... Neurological Surgeons Annual Meeting that they have joined ... surgery. The collaboration is the first of its ... improve patient outcomes. NICO,s BrainPath® interventional access technology ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... , , ... ... Presented at American College of Cardiology Meeting,in Atlanta and Published in the Lancet , ... ...
... U.S. Cancer Centers Involved , ... , , ... ... HUNTINGTON BEACH, California and AMSTERDAM , ...
Cached Medicine Technology:Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 2Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 3Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 4Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 5Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 6Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 2Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 3Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 4Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 5
... ReZoom intraocular lens is a second-generation ... patients with greater independence from glasses than ... provides a range of vision that monfocals ... Optics technology distributes light over five optic ...
... best potential for quality vision with ACRYSOF ... for spherical aberration by addressing the effects ... accomplished without increasing edge thickness. Human ... design that provides improved image quality.,MTF (measured ...
... FRx Defibrillator was designed to be as ... Defibrillator and shares many of its features, ... The Philips HeartStart Home Defibrillator is an ... for home use by untrained users. Although ...
Designed to meet the demanding requirements of scientific and laboratory,applications. Special cabinet incorporates industrial quality with a,heavy duty refrigeration system to maintain your valu...
Medicine Products: